Loading...
INSM logo

Insmed Community

NasdaqGS:INSM Community
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 23 Fair Values set on narratives written by author

Community Investing Ideas

INSM logo
Insmed

INSM: 2025 Launch Will Drive Respiratory Platform Expansion Amid Elevated Expectations

Key Takeaways Anticipated U.S. and international launches of brensocatib are key catalysts for significant revenue growth and new market penetration. Strategic investment in market access and R&D aims to sustain long-term profitability and support efficient product launches.Read more

View narrative
1users have liked this narrative
0users have commented on this narrative
7users have followed this narrative
US$204.5
2.4% undervalued intrinsic discount
AnalystConsensusTarget Fair Value
Revenue growth
89.48% p.a.
Profit Margin
28.34%
Future PE
75.74x
Share price in 2028
US$249.82